Skip to Content

Notice

Meeting of the Advisory Commission on Childhood Vaccines

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 36805

AGENCY:

Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

ACTION:

Notice of meeting.

SUMMARY:

In accordance with section 10(a)(2) of the Federal Advisory Committee Act, notice is hereby given that a meeting is scheduled for the Advisory Commission on Childhood Vaccines (ACCV). This meeting will be open to the public. Information about the ACCV and the agenda for this meeting can be obtained by accessing the following Web site: http://www.hrsa.gov/​advisorycommittees/​childhoodvaccines/​index.html.

DATES:

The meeting will be held on September 8, 2017, at 10:00 a.m. EDT.

ADDRESSES:

The address for the meeting is 5600 Fishers Lane, Rockville, MD, Conference Room 5N54. The public can join the meeting by:

1. (In Person) Persons interested in attending the meeting in person are encouraged to submit a written notification to: Annie Herzog, Division of Injury Compensation Programs (DICP), Healthcare Systems Bureau (HSB), HRSA, Rm. 8N146B, 5600 Fishers Lane, Rockville, Maryland 20857 or email: aherzog@hrsa.gov. Since this meeting is held in a federal government building, attendees will need to go through a security check to enter the building and participate in the meeting. This written notification is encouraged so that a list of attendees can be provided to make entry through security quicker. Persons may attend in person without providing written notification, but their entry into the building may be delayed due to security checks and the requirement to be escorted to the meeting by a federal government employee. To request an escort to the meeting after entering the building, call Amber Johnson at (301) 443-0129.

2. (Audio Portion) Call the conference phone number (800) 369-1833 and providing the following information:

Leader Name: Dr. Narayan Nair

Password: 6706374

3. (Visual Portion) Connect to the ACCV Adobe Connect Pro Meeting using the following URL: https://hrsa.connectsolutions.com/​accv/​. Participants should call and connect 15 minutes prior to the meeting to allow time for the logistics to be set-up. If you have never attended an Adobe Connect meeting, please test your connection using the following URL: https://hrsa.connectsolutions.com/​common/​help/​en/​support/​meeting_​test.htm.

Get a quick overview of the software at: http://www.adobe.com/​go/​connectpro_​overview.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Anyone requesting information regarding the ACCV should contact Annie Herzog, Program Analyst, DICP, HRSA in one of three ways: (1) Send a request to the following address: Annie Herzog, Program Analyst, DICP, HRSA, 5600 Fishers Lane, 8N146B, Rockville, Maryland 20857; (2) call (301) 443-6593; or (3) send an email to aherzog@hrsa.gov.

The ACCV will meet on Friday, September 8, 2017, beginning at 10:00 a.m. in the 5600 Fishers Lane Building, Rockville, Maryland 20857; however, meeting times and locations could change. For the latest information regarding meeting start time and location, please check the ACCV Web site: http://www.hrsa.gov/​advisorycommittees/​childhoodvaccines/​index.html.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

The ACCV was established by section 2119 of the Public Health Service Act (the Act) (42 U.S.C. 300aa-19), as enacted by Public Law (Pub. L.) 99-660, and as subsequently amended, and advises the Secretary of HHS (the Secretary) on issues related to implementation of the National Vaccine Injury Compensation Program (VICP).

Activities of the ACCV also include: Recommending changes to the Vaccine Injury Table on its own initiative or as the result of the filing of a petition; advising the Secretary in implementing section 2127 of the Act regarding the need for childhood vaccination products that result in fewer or no significant adverse reactions; surveying federal, state, and local programs and activities related to gathering information on injuries associated with the administration of childhood vaccines, including the adverse reaction reporting requirements of section 2125(b) of the Act; advising the Secretary on the methods of obtaining, compiling, publishing, and using credible data related to the frequency and severity of adverse reactions associated with childhood vaccines; consulting on the development or revision of Vaccine Information Statements; and recommending to the Director of the National Vaccine Program research related to vaccine injuries which should be conducted to carry out the VICP.

The agenda items for the meeting will include, but are not limited to, updates from DICP, Department of Justice, National Vaccine Program Office, Immunization Safety Office (Centers for Disease Control and Prevention), National Institute of Allergy and Infectious Diseases (National Institutes of Health) and Center for Biologics, Evaluation and Research (Food and Drug Administration). A draft agenda and additional meeting materials will be posted on the ACCV Web site (http://www.hrsa.gov/​advisorycommittees/​childhoodvaccines/​index.html) prior to the meeting. Agenda items are subject to change as priorities dictate.

Members of the public will have the opportunity to provide comments. Oral comments will be honored in the order they are requested and may be limited as time allows. Requests to make oral comments or provide written comments to the ACCV should be sent to Annie Herzog using the address and phone number above by September 4, 2017. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify Annie Herzog, using the address and phone number above at least 10 days prior to the meeting.

Start Signature

Amy McNulty,

Acting Director, Division of the Executive Secretariat.

End Signature End Supplemental Information

[FR Doc. 2017-16582 Filed 8-4-17; 8:45 am]

BILLING CODE 4165-15-P